Siena: The European Vaccine Hub (EVH) has been inaugurated in Siena, marking a pivotal step in strengthening Europe’s vaccine readiness and responsiveness during pandemics. This initiative aims to accelerate vaccine development to under four months from the identification of a pathogen’s genomic sequence.
According to Cyprus News Agency, the EVH will unify nationally-funded vaccine research and development investments at the EU level, encompassing a consortium of leading European organizations. These entities will pool their extensive expertise in vaccine discovery, development, clinical trials, and manufacturing to enhance Europe’s capability to protect its citizens against global health threats.
The EVH project is backed by the Commission’s Health Emergency Preparedness and Response Authority (HERA) under the EU4Health programme, with funding up to £102 million. The Hub will operate with an agile, decentralized structure, organizing collaborative research across Europe and ensuring sustainability beyond initial funding.
Key actions of the EVH include speeding up vaccine development, initiating a prototype vaccine strategy, leveraging public and private sector resources, and driving preclinical studies and trials. The Hub will also facilitate access to vaccine production facilities and clinical trial sites through industry partnerships.
The COVID-19 pandemic underscored the urgent need for rapid crisis response technologies, with prototype vaccines forming a crucial component of pandemic readiness. The EVH will integrate critical knowledge and expertise in vaccine development within broader international initiatives. It includes a Steering Committee for strategic decisions and a Coordination Team for operational management, supported by a stakeholders group and an External Advisory Committee.